Emerald Health Therapeutics (TSXV:EMH) has provided a corporate update on its recently closed and oversubscribed bought deal financing, together with a vision for growth in 2017.
As quoted in the press release:

“Following our successful financing with Dundee Capital Partners, Emerald is well capitalized and prepared for an exciting year of growth. Led by one of the industry’s most experienced scientific development teams, our focus has remained on downstream product development. From day one, Emerald has operated with the mandate of “enhancing health through cannabis science” and it’s these principles that will guide us as we forge ahead with our exciting and aggressive growth initiatives,” says Avtar Dhillon, MD, Executive Chairman of Emerald.
Significant expansion planned on 32-acre site in Metro Vancouver
As Emerald has been planning expansion, much of its research and development focus has involved increasing plant diversity and product offerings, as well as improving on its cultivation, manufacturing, and standardization processes in anticipation of a significant scale up. As the fifth applicant and eighth Licensed Producer in Canada, from the beginning Emerald has focused on quality of cultivation over quantity backed by strong research and development.
Phase 1 Expansion:


  • Plans are well underway to break ground in Q1 2017 to add 50,000 sq. ft. of cultivation space
  • This will be a state-of-the-art purpose built facility with anticipated capacity in excess of 5,000 kg per annum
  • Emerald’s first harvest is anticipated in early 2018 and will be ready for sale upon licensing

Phase 2 Expansion:

  • Emerald plans to scale-up in a modular fashion, with 50,000 sq. ft. additions to minimize the risk of product quality issues
  • Construction on Phase 2 to add an additional 50,000 sq. ft. of production area is anticipated to begin shortly after the commencement of Phase 1 and will be ready for production in 2018

The Company has the capacity to build out an aggregate of 1 million sq. ft. of total production space on its 32-acre Metro Vancouver property.

Click here to read the full press release.

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less